Search Results for: GW Pharmaceuticals Announces New Positive
Articles
December 12, 2016
GW Pharmaceuticals Announces New Positive Phase III Data December 12, 2016
GW Pharmaceuticals plc recently announced additional positive Epidiolex (cannabidiol or CBD) Phase III data in poster presentations at the 70th...
May 25, 2022
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis May 25, 2022
Phathom Pharmaceuticals, Inc. recently announced the US FDA has accepted for review the company’s New Drug Application (NDA) for vonoprazan...
January 27, 2022
Yamo Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study of L1-79 in Autism Spectrum Disorder January 27, 2022
Yamo Pharmaceuticals recently announced the first patient has been treated in a Phase 2 study of L1-79 in adolescents and...
January 18, 2022
EQRx Announces Two Lancet Oncology Publications of Positive Phase 3 Results of Sugemalimab in Stage III & Stage IV Non-Small Cell Lung Cancer January 18, 2022
EQRx, Inc. recently announced data from its partner CStone Pharmaceuticals’ two pivotal Phase 3 studies of the anti-PD-L1 monoclonal antibody...
July 8, 2021
Akston Biosciences Announces Positive Phase 1 Data for Second-Generation COVID-19 Vaccine Candidate July 8, 2021
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, recently announced positive results from a 60-subject, open-label, Phase...
February 20, 2020
Diasome Announces Positive Results from Phase 2 OPTI-1 Study February 20, 2020
Diasome Pharmaceuticals, Inc. recently announced positive results from its Phase 2 OPTI-1 study of injectable hepatocyte directed vesicle (HDV) added to...
June 6, 2019
Foamix Announces Publication of Phase 3 FMX101 Study June 6, 2019
Foamix Pharmaceuticals Ltd. recently announced the peer review publication of the Phase 3 study FX2017-22 (Study 22) in the Journal...
June 11, 2012